We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
In an unusual move, Celgene has backed out of a $55 million settlement to clear accusations of anticompetitive behavior over its cancer treatments Revlimid and Thalomid, attorneys for the plaintiffs announced Wednesday. Read More
The Federal Circuit Court of Appeals gave Amgen another chance to prove that Amneal’s planned generic of its hyperparathyroidism treatment Sensipar (cinacalcet) infringes on its patent. Read More
The study’s authors “erroneously state that FDA abandoned efforts to evaluate the impact of the ER/long-acting REMS program on prescriber behavior and patient outcomes,” the agency said. Read More
Allergan and Ironwood Pharmaceuticals reached a settlement with Sandoz to resolve patent litigation over Sandoz’s planned generic versions of their co-developed irritable bowel syndrome treatment Linzess. Read More